Key result
Serum Lumican levels predict LGE in HCM with ~68% sensitivity.
Why the study?
Hypertrophic cardiomyopathy is a leading cause of sudden cardiac death, and the relationship between the fibrosis indicator serum Lumican and the presence and extent of myocardial fibrosis in HCM needed evaluation.
Are serum Lumican levels associated with the presence and extent of myocardial fibrosis in patients with hypertrophic cardiomyopathy?
Observational (n=114)
Are serum Lumican levels associated with the presence and extent of myocardial fibrosis in patients with hypertrophic cardiomyopathy?
Serum Lumican levels may serve as a useful biomarker for predicting the presence and extent of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
May support Lumican as noninvasive fibrosis marker in HCM; leaves open prospective validation before clinical use.
OBJECTIVE: Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death in young individuals. Lumican, is an indicator of fibrosis. We aimed to evaluate the relation between serum Lumican levels and presence and extent of myocardial fibrosis in HCM. METHODS: The patients diagnosed with HCM between June 2022 and March 2023 were enrolled consecutively in this prospective study. Age and gender-matched healthy individuals formed control group. Two groups were generated according to extent of late gadolinium enhancement (LGE) in HCM patients. RESULTS: A total of 114 patients were enrolled. Serum Lumican, NT-proBNP levels and maximum wall thickness were revealed as independent risk factors associated with LGE. A cut-off value of 9.06 for Lumican was associated with 67.8% sensitivity and 65.5% specificity in prediction of LGE. CONCLUSION: Myocardial fibrosis is one of the important mechanisms in HCM pathophysiology. LGE on cardiac magnetic resonance imaging allows comprehensive evaluation of myocardial fibrosis, the support of diagnosis with a biomarker would be beneficial in clinical practice. Our study revealed that serum Lumican level is an independent predictor of severe LGE in HCM patients. Further studies with larger patient numbers may clarify the importance of Lumican in HCM pathophysiology.
No takes yet. Share an insight, caveat, or question.
Hancıoğlu et al. (2025) conducted an observational in Hypertrophic cardiomyopathy (n=114). Serum Lumican vs. Healthy individuals was evaluated on Presence and extent of late gadolinium enhancement (LGE). Serum Lumican levels independently predicted late gadolinium enhancement in hypertrophic cardiomyopathy, with a cut-off of 9.06 yielding 67.8% sensitivity and 65.5% specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: